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Abstract
Background: Few studies have investigated factors associated with discontinuation of employment in patients
with CFS/ME or quantified its impact on productivity.
Methods: We used patient-level data from five NHS CFS/ME services during the period 01/04/2006-31/03/2010
collated in the UK CFS/ME National Outcomes Database. We used logistic regression to identify factors associated
with discontinuation of employment. We estimated UK-wide productivity costs using patient-level data on duration
of illness before assessment by a CFS/ME service, duration of unemployment, age, sex and numbers of patients, in
conjunction with Office for National Statistics income and population data.
Results: Data were available for 2,170 patients, of whom 1,669 (76.9%) were women. Current employment status
was recorded for 1,991 patients (91.8%), of whom 811 patients (40.7%) were currently employed and 998 (50.1%)
had discontinued their employment “because of fatigue-related symptoms”. Older age, male sex, disability, fatigue,
pain, and duration of illness were associated with cessation of employment. In a multivariable model, age, male
sex, and disability remained as independent predictors. Total productivity costs among the 2,170 patients due to
discontinuation of employment in the years preceding assessment by a specialist CFS/ME service (median duration
of illness = 36 months) were £49.2 million. Our sample was equivalent to 4,424 UK adults accessing specialist
services each year, representing productivity costs to the UK economy of £102.2 million. Sensitivity analyses
suggested a range between £75.5-£128.9 million.
Conclusions: CFS/ME incurs huge productivity costs amongst the small fraction of adults with CFS/ME who access
specialist services.
Background
Chronic Fatigue Syndrome or Myalgic Encephalopathy
(CFS/ME) is defined as persistent or recurrent debilitat-
ing fatigue that is not lifelong, the result of ongoing
exertion, alleviated by rest, or explained by other condi-
tions, and that results in a substantial reduction in activ-
ity [1-3]. CFS/ME is heterogeneous [4] and relatively
common with an estimated prevalence from population
surveys of between 0.2% and 2.6% [5-10]. Adults with
CFS/ME are unwell for a long time, with a median
duration of illness of 6.3 years [11].
Few studies have investigated the impact of CFS/ME
on employment and productivity. A systematic review of
the literature that collated employment data from a vari-
ety of studies between 1988 and 2001 found that 54% of
patients with CFS/ME were unemployed [12]. Estimates
of productivity costs to the US economy have varied
widely, depending mainly on the estimated prevalence of
CFS/ME in the communities surveyed: $9 billion (Kan-
sas, 1994) [13], $17 billion (Illinois, 1995-1998) [14], $37
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sis has been performed on data from the UK.
In the UK, specialist CFS/ME clinical teams provide a
range of treatments according to National Institute for
Health and Clinical Excellence (NICE) guidelines [3].
Access to these services throughout the UK is variable
[16,17], and the proportion of people with CFS/ME who
are referred to specialist services is unknown. Amongst
those who are referred to a specialist service, the impact
of their illness on employment and income has not been
quantified. Here we use data on patients attending 5
specialist CFS/ME services in the UK to investigate the
clinical and demographic factors associated with discon-
tinuation of employment, to estimate earnings lost as a
consequence of CFS/ME, and to estimate productivity
costs to the UK economy incurred by patients with
CFS/ME prior to assessment by a specialist service.
Methods
Study population
The UK CFS/ME National Outcomes Database (NOD)
collects assessment and follow-up data on patients
attending or visited by NHS specialist CFS/ME services.
The aim of the NOD is to enable benchmarking and
evaluation of these services. All contributing clinical
teams are members of the British Association for CFS/
ME (BACME). BACME comprises more than 40 adult
and 12 paediatric teams, together assessing more than
6,000 adults and children each year. We included in our
study all patients ≥ 18 years and ≤ 64 years old who had
attended specialist CFS/ME services provided by clinical
teams in Bristol (Frenchay), Wells (Somerset), Leeds
(Leeds & West Yorkshire), Barts and The London, and
Epsom and St Helier (South West London and Surrey)
during the period 01/04/2006 to 31/03/2010. These
teams had assessed and treated a constant number of
patients each year during the study period. For each
team, patients were referred with a diagnosis of CFS/ME
and this was confirmed at assessment according to CDC
diagnostic criteria [1,2]. Other teams that contributed
data to the NOD during this period were excluded
either because they contributed data for a small number
of patients or because their CFS/ME service had been
established relatively recently.
Patient-level data
We collected the following data at the time of assess-
ment by the CFS/ME service: age, sex, ethnicity, diag-
nostic criteria, and self-reported duration of illness (time
elapsed, in months, between onset of symptoms and
clinical assessment). Current employment status was
recorded in 4 categories: i) “Currently employed full- or
part-time"; ii) “Temporarily discontinued because of fati-
gue-related symptoms"; iii) “Indefinitely discontinued
because of fatigue-related symptoms"; iv) “Other”.I n
addition, patients completed the following inventories
prior to assessment: 11-item Chalder Fatigue Scale [18];
10-item SF-36 physical function subscale [19], 14-item
Hospital Anxiety and Depression Scale (HADS) [20] and
a Visual Analogue Pain Rating Scale (score of 0 for “no
pain” and 100 for “pain as bad as possible”). The
Chalder Fatigue Scale was scored using the 0-3 method
for scoring each question (0 “Less than usual”,1“No
more than usual”,2“More than usual”,3“Much more
than usual”). On the physical function sub-scale of the
SF-36, patients scored 0 ("Yes, limited a lot”)5( " Y e s ,
limited a little”) or 10 ("No, not limited at all”)f o re a c h
question, so that the most disabled patients scored 0
while those with unaffected physical function scored
100. Inventory total scores (and each HADS sub-scale
score) were coded as missing if > 1 question was unan-
swered; if only one item was missing, an adjusted total
score was calculated.
Factors associated with discontinuation of employment
We used Chi-squared tests and Student’st - t e s tt oc o m -
pare the characteristics (age, sex, duration of illness, fati-
gue, disability, anxiety, depression and pain) of patients
who were in employment at time of assessment with the
characteristics of patients who had temporarily or per-
manently discontinued employment (before assessment)
due to their illness. These characteristics were included
in a logistic regression model to identify factors inde-
pendently associated with discontinuation of employ-
ment among patients for whom complete data on all
characteristics were available. So that regression coeffi-
cients for the different inventories were comparable,
they were rescaled so that the range for each was
approximately 0 - 10.
Discontinuation of employment
In May 2010, the NOD forms and questionnaires were
amended to include more detailed questions about the
effect of CFS/ME on employment, specifically, patients
were asked to give the “Date when reduced hours/sick
leave/unemployment began”. We used responses to this
question to estimate the duration of unemployment as a
fraction of the duration of illness in an external sample
of patients ≥ 18 years old assessed by any team contri-
buting data to the NOD during the period 01/06/2010
to 30/11/2010. We used the mean value of this fraction
in our calculations, stratified by sex but not by age (due
to insufficient numbers in some of the age strata).
Per patient productivity costs due to discontinuation of
employment
Productivity costs were estimated using average
annual earnings data by sex and age group obtained
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were used to estimate age- and sex-specific cumula-
tive loss of earnings due to discontinuation of
employment prior to assessment by a NHS CFS/ME
specialist clinical team. The total productivity costs
in the patient sample were estimated as the product
of: the number of patients assessed who had a new
or confirmed diagnosis of CFS/ME; the fraction who
had discontinued their employment; the median
duration of illness; the proportional duration of
unemployment (mean ‘duration of unemployment’/
mean ‘duration of illness’)f r o mt h ee x t e r n a ls a m p l e ;
and mean annual income. This product was divided
by the number of patients to yield an estimated total
loss per person.
Nationwide productivity costs
Access to CFS/ME specialist assessment throughout the
UK is variable [16,17]. The five CFS/ME teams contri-
buting data to this study represent areas of the country
that currently have higher levels of access. We used
data from these five centres to extrapolate and estimate
the potential nationwide productivity costs due to CFS/
ME in patients prior to specialist assessment. The clini-
cal teams in our study were asked to identify the Pri-
mary Care Trusts (PCTs) from which the majority of
patients were referred. The annual proportion of the
population who access specialist assessment was esti-
mated by dividing the number of patients in the sample
by the number of study years (four) and then by the
estimated population in the PCTs served by the teams
in our study in each age and sex stratum [22]. These
proportions were multiplied by UK population estimates
[22] to estimate the total population of people with
CFS/ME in the UK who might receive specialist assess-
ment each year. The nationwide productivity costs due
to CFS/ME prior to specialist assessment were esti-
mated for this population using age and sex stratified
earnings data, as previously described. In two one-way
sensitivity analyses, we used the lower and upper
bounds of the 95% confidence intervals for the fractions
of those who had discontinued their employment and
the fraction ‘duration of unemployment’/’duration of ill-
ness’ to estimate upper and lower bounds for the total
UK loss.
Ethical approval
The North Somerset & South Bristol Research Ethics
Committee decided that the collection and analysis of
CFS/ME patient data were part of service evaluation and
as such did not require ethical review by a NHS
Research Ethics Committee or approval by NHS
Research and Development offices (REC reference num-
ber 07/Q2006/48).
Results
Description of adult CFS/ME cohort in the National
Outcomes Database
Clinical assessment data were available for 2,170
patients, of whom 1,669 (76.9%) were women. The
mean ages of men and women were 41.4 years and 38.6
years, respectively (Student’s t test P < 0.001). Current
employment status was recorded for 1,991 patients
(91.8%), of whom 811 patients (40.7%) reported their
status as “Currently employed"; 322 (16.2%) as “Tem-
porarily discontinued because of fatigue-related symp-
toms"; 676 (34.0%) as “Permanently discontinued
because of fatigue-related symptoms"; and 182 (9.1%) as
“Other”. Of the 811 patients who were currently
employed and the 998 patients (50.1%) who had discon-
tinued their employment, complete questionnaire data
(duration of illness, Chalder Fatigue, SF-36, HADS, and
Visual Analogue Pain) were collected at time of clinical
assessment for 641 (79.0%) and 756 (75.8%) patients,
respectively.
Factors associated with discontinuation of employment
Men, people in older age groups, and people who had
been ill for longer were more likely to have ceased
employment due to their fatigue-related symptoms
(Table 1): the proportion of patients in the 18 - 21 year
o l da g eg r o u pw h oh a dd i s c o n t i n u e dt h e i re m p l o y m e n t
was 42.7%, compared with 65.4% of patients 50 - 59
years old; 60.3% of men were no longer employed, com-
pared with 53.6% of women; median duration of illness
was 4 years among patients who had ceased working,
compared with 3 years among patients who were cur-
rently employed. There was an overall downward trend
(Ptrend = 0.03) in median duration of illness among all
patients between 2006 (42 months) and 2010 (36
months).
The clinical characteristics (fatigue, disability, anxiety,
depression, and pain) of those who had ceased working
indicated a greater severity of illness than was experi-
enced by people who were currently employed. Most
notably, disability (as measured by the SF-36 physical
function questionnaire) showed a 20-point difference (30
compared with 50) on a scale of 0 - 100, and pain (mea-
sured on a 0 - 100 visual analogue pain rating scale)
showed a 12-point difference (55 compared with 43).
In logistic regression models (adjusted for centre and
year of assessment): older age, longer duration of illness,
worse fatigue, poorer physical function, and pain were
strongly associated with cessation of employment; male
sex, greater anxiety and depression were weakly asso-
ciated with cessation of employment (Table 2). In a
multivariable logistic regression model that included all
of these variables (Table 2), older adults and men were
more likely to have discontinued their employment, but
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ployment was poor physical function. Mutual adjust-
ment for all patient characteristics slightly attenuated
the association of older age with discontinuation of
employment, but the association with sex was strength-
ened. The association of SF-36 score with discontinua-
tion of employment was unaffected in strength and
magnitude.
Discontinuation of employment
Date of discontinuation of employment was available for
60 patients (22 male, 38 female) who were assessed
between 01/06/2010 and 30/11/2010 for whom data had
been obtained from the amended assessment forms.
Median (interquartile range (IQR)) of duration of illness
was 26 (14 - 108) months; median (IQR) of ‘duration of
unemployment’ w a s1 1( 5-2 6 )m o n t h s .T h ef r a c t i o n
Table 1 Characteristics of CFS/ME patients in current and discontinued employment due to fatigue-related symptoms
(IQR = interquartile range)
Currently employed Employment discontinued P-value*
Age (years) n = 811 n = 998
18 - 21 59 (57.3%) 44 (42.7%)
22 - 29 153 (49.8%) 154 (50.2%)
30 - 39 265 (51.5%) 250 (48.5%)
40 - 49 202 (42.9%) 269 (57.1%)
50 - 59 119 (34.6%) 225 (65.4%)
60+ 13 (18.8%) 56 (81.2%) < 0.001
Sex n = 811 n = 998
Female 643 (46.4%) 743 (53.6%)
Male 168 (39.7%) 255 (60.3%) 0.02
Duration of illness (months) n = 743 n = 878
Median (IQR) 35 (15 - 84) 48 (18 - 120) < 0.001
Chalder Fatigue (0 - 33) n = 752 n = 911
Median (IQR) 25 (21 - 30) 27 (23 - 31) < 0.001
SF-36 physical function (scale 0 - 100) n = 744 n = 901
Median (IQR) 50 (35 - 65) 30 (20 - 45) < 0.001
HADS anxiety (scale 0 - 21) n = 751 n = 916
Median (IQR) 10 (7 - 13) 11 (7 - 14) 0.02
HADS depression (scale 0 - 21) n = 753 n = 919
Median (IQR) 9 (6 - 12) 10 (7 - 13) < 0.001
Visual Analogue Pain (scale 0 - 100) n = 717 n = 886
Median (IQR) 43 (18 - 65) 55 (26 - 72) < 0.001
* Chi-squared test for categorical variables; Mann-Whitney two-sample test for continuous variables
Table 2 Associations of CFS/ME patient characteristics with discontinuation of employment: analyses based on
patients with complete data for all variables in table (N = 1,397 of whom 641 (45.9%) currently employed, 756
(54.1%) discontinued employment)
Variable* Partially-adjusted odds ratio**
(95% CI)
P-value Fully-adjusted odds ratio***
(95% CI)
P-value
10-year age group 1.31 (1.19, 1.44) < 0.001 1.16 (1.05, 1.29) 0.005
Sex (female vs male) 0.76 (0.59, 0.98) 0.03 0.62 (0.46, 0.82) 0.001
Duration of illness (years) 1.03 (1.01, 1.05) 0.003 1.01 (0.99, 1.03) 0.36
Chalder Fatigue 1.20 (1.12, 1.29) < 0.001 1.02 (0.93, 1.11) 0.68
SF-36 (physical function) 0.70 (0.66, 0.74) < 0.001 0.71 (0.67, 0.76) < 0.001
HADS anxiety 1.04 (1.00, 1.09) 0.06 0.98 (0.92, 1.04) 0.42
HADS depression 1.18 (0.98, 1.25) 0.06 1.05 (0.98, 1.14) 0.16
Visual Analogue Pain 1.12 (1.08, 1.17) < 0.001 1.00 (0.96, 1.05) 0.84
* Chalder Fatigue, SF-36, HADS, and Visual Analogue Pain measures were re-scaled to range from 0 to 10. For SF-36, odds ratio < 1 indicates that higher levels of
disability are positively associated with discontinuation of employment.
** Adjusted only for centre and year of assessment (for continuous measures, odds ratio is per unit increase)
*** Adjusted for centre, year of assessment and all variables in table (for continuous measures, odds ratio is per unit increase)
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mean value of 0.52 (95% CI 0.38, 0.66) for men and 0.47
(95% CI 0.35, 0.59) for women, indicating that disconti-
nuation of employment occurred, on average, at the
midpoint of the interval between onset of illness and
assessment by a specialist CFS/ME service for both
sexes.
Productivity costs due to discontinuation of employment
Data on employment status and duration of illness were
available for 82.4% (413/501) and 82.5% (1,377/1,669) of
men and women, respectively. Patients missing these
data were slightly older (mean age 41.0 years vs 38.8
years, t test P = 0.002) and had slightly higher Chalder
Fatigue scores (26.3 vs 24.4, t test P < 0.001) than those
with complete data, but were similar in all other charac-
teristics. The estimated productivity costs due to discon-
tinuation of employment based on data collected from
2,170 patients (501 men and 1,669 women) attending
the five CFS/ME specialist services in our study between
04/2006 and 03/2010 are shown in Table 3.
The total productivity costs among the 2,170 patients
in our study were £22.3 million for men (equivalent to
£44,515 per patient) and £26.9 million for women
(equivalent to £16,130 per patient), giving a total loss of
£49.2 million (equivalent to £22,684 per patient). The
prevalence of CFS/ME referred for specialist assessment
was much higher in women (17.7 per 100,000) than in
men (5.3 per 100,000) in the five CFS/ME services in
our study; the overall prevalence of CFS/ME referred for
specialist assessment was 11.54 per 100,000. By extrapo-
lating these estimates to the UK population, we esti-
mated that each year 4,424 working age adults with
CFS/ME might be referred for specialist assessment, and
that this group would already have incurred productivity
costs of £102.2 million due to their illness by the time
of the assessment.
The lower and upper bounds of the 95% confidence
intervals for the fraction ‘duration of unemployment’/
’duration of illness’ (0.38 - 0.66) in men, (0.35 - 0.59) in
women, corresponded to productivity costs of £75.5 -
£128.9 million per year; the lower and upper bounds of
the 95% confidence intervals for the proportions unem-
ployed corresponded to productivity costs of £86.2 -
£117.5 million per year.
Discussion
This is the first study to estimate the productivity costs
of patients with CFS/ME who access specialist services.
We have estimated an annual productivity cost to the
UK economy of approximately £100 million. The total
productivity costs of CFS/ME are likely to be substan-
tially higher because many adults with CFS/ME are not
referred to specialist clinical teams. Our estimates for
the proportion of the population who access specialist
services are 20-40 times lower than the estimated preva-
lence of CFS/ME among adults in the USA based on
community surveys [8,23]. Although we found a
decrease in duration of illness over the study period,
suggesting that awareness and availability of CFS/ME
specialist services improved during the period of our
study, the median duration of illness in 2010 (36
months) was still much longer than the 6 months
recommended by NICE for referral of mild cases of
CFS/ME to specialist services [3]. The situation in those
parts of the UK that are not covered by established spe-
cialist CFS/ME services is likely to be worse.
The strength of our study is that it is based on routi-
nely-collected clinical data from several teams across the
UK. Hence, the patients in our study are likely to be
representative of adults who have been referred to CFS/
ME specialist services within the NHS over the past 4
years. We had no data with which to assess the rate at
which people with CFS/ME recover and return to work,
either with or without specialized treatment. According
to a systematic review of the literature, the proportion
of adults in employment increased following interven-
tions for CFS/ME (individualised rehabilitation, cogni-
tive behavioural therapy and exercise therapy) and
decreased in observational studies with no intervention
[12]. Evidence from a recent evidence trial of cognitive
behavioural therapy and graded exercise therapy indi-
cated a recovery rate of 30-40% one year after treatment
[24]. Our analysis was based on income data from 2009,
which we applied retrospectively to patients who may
have discontinued their employment several years ear-
lier, e.g. female patients in the 60 - 64 years age group
assessed in 2006 with a median duration of illness of 7
years were assumed to have discontinued employment
in 2002. We do not know whether socioeconomic status
is associated with CFS/ME and with access to services,
therefore we were unable to weight our loss of earnings
estimates. Also, by valuing time off work using average
earnings we are assuming that the worker is not
replaced, for example from those currently unemployed,
and that there is a long-term cost to society. Alternative
friction-cost approaches to valuing lost productivity
would result in a lower estimate of the productivity
costs of CFS/ME [25].
The proportion of patients in our study who had dis-
continued employment (50%) is consistent with an esti-
mate from a systematic review of unemployment due to
CFS (54%) [12]. That disability was the main indepen-
dent predictor of discontinuation of employment in a
multivariable model is consistent with a study of
employees on long-term sick l e a v ed u et of a t i g u e[ 2 6 ] .
Our finding suggests that people with CFS/ME continue
in employment despite the primary (fatigue and pain)
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Page 5 of 8Table 3 Estimated loss of productivity due to CFS/ME based on patients referred to 5 NHS specialist services (2006 - 2010)
Sex and
age
(years)
N
a Discontinued
employment
(%)
b
Median
duration of
illness
(months)
b
Mean
annual
income
(£)
c
Total loss of
productivity
(£)
d
Loss
per
person
(£)
e
Population
in PCTs in
study
f
Proportion of population
who access services (per
100,000 per year)
UK
population
(1000’s)
Number of people
who might access
services per year (UK)
Productivity costs
among people who
might access services
(UK)
Male
18 - 21 26 40% 21 11,546 109,271
22 - 29 72 48% 30 23,460 1,054,011 11,870 655,664 3.74 5,135 192 2,277,502
30 - 39 128 53% 72 35,172 7,444,534 58,160 554,200 5.77 4,069 235 13,663,983
40 - 49 127 56% 60 39,390 7,283,684 57,352 535,400 5.93 4,523 268 15,383,619
50 - 59 116 65% 48 36,590 5,738,483 49,470 414,100 7.00 3,690 258 12,782,017
60 - 64 32 59% 31 26,505 672,223 21,007 190,800 4.19 1,818 76 1,601,287
Subtotals 501 22,302,206 44,515 2,350,164 5.33 19,234 1,030 45,708,408
Female
18 - 21 150 25% 36 8,875 469,266
22 - 29 294 43% 26 18,508 2,382,677 6,423 638,346 17.39 4,922 856 5,497,849
30 - 39 461 43% 36 22,047 6,162,231 13,367 548,400 21.02 4,086 858 11,475,526
40 - 49 411 53% 48 20,880 8,550,786 20,805 541,600 18.97 4,631 879 18,280,147
50 - 59 281 61% 55 19,893 7,345,405 26,140 423,200 16.60 3,796 630 16,469,450
60 - 64 72 60% 87 13,662 2,011,101 27,932 200,000 9.00 1,901 171 4,779,382
Subtotals 1,669 26,921,466 16,130 2,351,546 17.74 19,335 3,394 56,502,353
Totals 2,170 49,223,672 22,684 4,701,710 11.54 4,424 102,210,761
a) Numbers of patients with CFS/ME assessed by 5 specialist services that had contributed constant patient numbers each year to the CFS/ME National Outcomes Database over the period 04/2006 - 03/2010
b) Based on subset of patients (413 male, 1,377 female) for whom data on occupation and duration of illness were recorded in the CFS/ME National Outcomes Database
c) Source: Office for National Statistics “Annual Survey of Hours and Earnings, 2009”
d) (N × fraction unemployed × (median duration of illness × F) × (mean annual income/12)) where F = 0.52 for men, F = 0.47 for women (F = duration of unemployment/duration of illness)
e) The 18-21 and 22-29 age groups were combined into a single 18-29 age group to match PCT population age strata
f) Source: Office for National Statistics “Mid-2008 Population Estimates by Primary Care Organization”
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8and secondary effects (depression and anxiety) of CFS/
ME. Instead, loss of physical capacity is the ultimate
arbiter of inability to continue working. That women
and younger people are less likely to discontinue work
is consistent with findings from a US community-based
study [13]. A UK-based study of patients presenting
with chronic fatigue in a primary care setting reported
that loss of employment over the preceding 6-month
period had a mean cost per person of £2,350 (95% CI
£1734 - £2966) although it is unclear whether all of
these patients had CFS/ME [27]. The equivalent cost
from our data (based on the weighted average of half
the mean annual income) would be £5,753. This figure
may indicate the higher productivity costs of CFS/ME vs
chronic fatigue [28]. The same study estimated that pro-
ductivity costs represent 61% of the total costs of CFS/
ME; the remaining costs were attributed to health
resource use (13%) and informal care (26%) [27].
Conclusion
T h em a i ni m p l i c a t i o no fo u rf i n d i n g si st h a te f f e c t so n
employment and productivity must be accounted for in
estimates of the cost-effectiveness of CFS/ME interven-
tions and service provision. Screening for CFS/ME by
general practitioners and occupational therapists could
be cost-effective in conjunction with early intervention
for treating CFS/ME. We have quantified the impact of
CFS/ME among patients who access specialist CFS/ME
services in terms of loss of employment and productiv-
ity, i.e. as an indirect cost to the UK economy. In addi-
tion to this indirect cost, health resource use and
welfare payments impose direct costs, and families of
patients must bear the costs of informal care, often
reducing their own working hours [27]. In young adults,
disruption of education reduces productivity in later
years [15]. Above and beyond these financial costs, CFS/
ME has a huge impact on quality of life [29]. Research
is urgently needed to establish whether wider access and
earlier referral to specialist CFS/ME services is a cost-
effective way of reducing productivity losses.
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